Genomes and Genes
Beatriz M Carreno
Affiliation: Wyeth Research
- BTLA: a new inhibitory receptor with a B7-like ligandBeatriz M Carreno
Inflammation, Wyeth Research, 200 Cambridge Park Drive, Cambridge, MA 02140, USA
Trends Immunol 24:524-7. 2003..Thus, cytotoxic T lymphocyte antigen-4 (CTLA-4), programmed death-1 (PD-1) and BTLA comprise an expanding set of inhibitory receptors expressed on lymphocytes...
- Cytotoxic T-lymphocyte antigen-4 and programmed death-1 function as negative regulators of lymphocyte activationLaura L Carter
Wyeth Research, Cambridge, MA 02140, USA
Immunol Res 28:49-59. 2003..The PD-L/PD-1 pathway, on the other hand, may primarily attenuate, limit, and/or terminate T-, B-, and myeloid cell activation/effector function at sites of inflammation in the periphery...
- PD-1/PD-L1, but not PD-1/PD-L2, interactions regulate the severity of experimental autoimmune encephalomyelitisLaura L Carter
Inflammation, Wyeth Research, 200 CambridgePark Dr, Cambridge, MA 02140, United States
J Neuroimmunol 182:124-34. 2007..These results demonstrate that interactions between PD-1/PD-L1, but not PD-1/PDL-2, are crucial in attenuating T cell responses in EAE...
- The B7 family of ligands and its receptors: new pathways for costimulation and inhibition of immune responsesBeatriz M Carreno
Genetics Institute Wyeth Research, 87 Cambridge Park Drive, Cambridge, Massachusetts 02140, USA
Annu Rev Immunol 20:29-53. 2002..Understanding these pathways will allow development of new strategies for therapeutic intervention in immune-mediated diseases...
- The human IL-17F/IL-17A heterodimeric cytokine signals through the IL-17RA/IL-17RC receptor complexJill F Wright
Department of Inflammation, Wyeth Research, Cambridge, MA 02140, USA
J Immunol 181:2799-805. 2008..However, the distinct affinities of the receptor components for IL-17A, IL-17F, and IL-17F/IL-17A heterodimer can be exploited to differentially affect the activity of these cytokines...
- The B7 family of immune-regulatory ligandsMary Collins
Wyeth Research, 200 Cambridge Park Drive, Cambridge, MA 02140, USA
Genome Biol 6:223. 2005..Manipulation of the signals delivered by B7 ligands has shown potential in the treatment of autoimmunity, inflammatory diseases and cancer...
- Therapeutic opportunities in the B7/CD28 family of ligands and receptorsBeatriz M Carreno
Inflammation, Wyeth Research, 200 CambridgePark Drive, Cambridge, Massachusetts 02140, USA
Curr Opin Pharmacol 5:424-30. 2005..Indeed, recent Phase I clinical studies using agonists and antagonists of the CD28/CTLA-4/B7 pathway have shown promise in inflammatory diseases and cancer...
- Identification of an interleukin 17F/17A heterodimer in activated human CD4+ T cellsJill F Wright
Department of Inflammation, Wyeth Research, Cambridge, Massachusetts 02140, USA
J Biol Chem 282:13447-55. 2007..These data suggest that the IL-17F/IL-17A heterodimer may contribute to the T cell-mediated immune responses...
- PD-1:PD-L inhibitory pathway affects both CD4(+) and CD8(+) T cells and is overcome by IL-2LauraL Carter
Wyeth Genetics Institute, Cambridge, MA 02140, USA
Eur J Immunol 32:634-43. 2002..However, CD8(+) T cells may be more sensitive to modulation by the PD-1:PD-L pathway because of their intrinsic inability to produce significant levels of IL-2...
- Duplication of primate and rodent B7-H3 immunoglobulin V- and C-like domains: divergent history of functional redundancy and exon lossVincent Ling
Wyeth Research, 200 Cambridge Park Drive, 02140, Cambridge, MA, USA
Genomics 82:365-77. 2003..These results suggest independent, but convergent, paths of B7-H3 active domain duplication followed by divergent histories of exon degeneration in rodents and exon maintenance by humans...
- Surface cytotoxic T lymphocyte-associated antigen 4 partitions within lipid rafts and relocates to the immunological synapse under conditions of inhibition of T cell activationPeter J Darlington
The Biotherapeutics and Transplantation and Immunobiology Groups, The John P Robarts Research Institute, and The Departments of Microbiology and Immunology, and Medicine, The University of Western Ontario, London, Ontario N6A 5K8, Canada
J Exp Med 195:1337-47. 2002..These data demonstrate that CTLA-4 within lipid rafts migrates to the IS where it can potentially form lattice structures and inhibit T cell activation...
- Inhibition of CTLA-4 function by the regulatory subunit of serine/threonine phosphatase 2AMiren L Baroja
Transplantation and Immunobiology Group, John P Robarts Research Institute, University of Western Ontario, 100 Perth Drive, London, Ontario N6A 5K8, Canada
J Immunol 168:5070-8. 2002..Our data imply that the lysine-rich motif in CTLA-4 may be used to identify small molecules that block its binding to PP2A and act as agonists for CTLA-4 function...
- Role of IL-17A, IL-17F, and the IL-17 receptor in regulating growth-related oncogene-alpha and granulocyte colony-stimulating factor in bronchial epithelium: implications for airway inflammation in cystic fibrosisFlorencia McAllister
Lung Immunology and Host Defense Laboratory, Department of Pediatrics, University of Pittsburgh, Pittsburgh, PA 15213, USA
J Immunol 175:404-12. 2005..aeruginosa. IL-23 and the downstream cytokines IL-17A and IL-17F are critical molecules for proinflammatory gene expression in HBE cells and are likely involved in the proinflammatory cytokine network involved with CF pathogenesis...
- Program death-1 engagement upon TCR activation has distinct effects on costimulation and cytokine-driven proliferation: attenuation of ICOS, IL-4, and IL-21, but not CD28, IL-7, and IL-15 responsesFrann Bennett
Cambridge Antibody Technology, Abington, United Kingdom
J Immunol 170:711-8. 2003....
- TCR subunit specificity of CTLA-4-mediated signalingEric Siu
The FOCIS Centre for Clinical Immunology and Immunotherapeutics, Robarts Research Institute, London, Ontario, Canada N6A 5K8
J Leukoc Biol 74:1102-7. 2003..Our results suggest that the target specificity of CTLA-4 is determined by its coligation with any given transmembrane receptor rather than by its intracellular mediators...
- Conversion of CTLA-4 from inhibitor to activator of T cells with a bispecific tandem single-chain Fv ligandJoaquin Madrenas
Federation of Clinical Immunology Societies Centre for Clinical Immunology and Immunotherapeutics, Robarts Research Institute, and Department of Microbiology, University of Western Ontario, London, Ontario, Canada
J Immunol 172:5948-56. 2004..Our data demonstrate that the cytoplasmic domain of CTLA-4 has an inherent plasticity for signaling that can be exploited therapeutically with recombinant ligands for this receptor...
- Blockade of programmed death-1 engagement accelerates graft-versus-host disease lethality by an IFN-gamma-dependent mechanismBruce R Blazar
University of Minnesota Cancer Center and Department of Pediatrics, Minneapolis, MN 55455, USA
J Immunol 171:1272-7. 2003..These data indicate that PD-1 ligation down-regulates GVHD through modulation of IFN-gamma production and suggest a novel therapeutic target for inhibiting GVHD lethality...
- Engagement of glucocorticoid-induced TNFR family-related receptor on effector T cells by its ligand mediates resistance to suppression by CD4+CD25+ T cellsGeoffrey L Stephens
Cellular Immunology Section, Laboratory of Immunology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
J Immunol 173:5008-20. 2004..The down-regulation of GITR-L by inflammatory stimuli may enhance the susceptibility of effector T cells to suppressor activity during the course of an infectious insult...
- Human major histocompatibility complex (MHC) class I molecules with disulfide traps secure disease-related antigenic peptides and exclude competitor peptidesSteven M Truscott
Department of Pathology and Immunology, Division of Oncology, Washington University School of Medicine, St Louis, Missouri 63110, USA
J Biol Chem 283:7480-90. 2008..The mechanistic and practical applications of these findings for vaccine development and T cell isolation/enumeration are discussed...